Cartesian Therapeutics Advances CAR-T Therapy Pipeline with FDA Approval for Myositis Trial and Positive Phase 3 Progress
核心洞察
Cartesian Therapeutics received FDA acceptance for its IND application to initiate a Phase 2 trial of Descartes-08 in myositis (搜索), with potential for a single pivotal trial starting in the first half of 2026.
The company's Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (搜索) remains on track, with the therapy recently named to Nature Medicine's list of eleven clinical trials that will shape medicine in 2026.
New Nature Medicine publications revealed that Descartes-08 achieved precision retuning of autoreactivity and demonstrated deep, durable responses through 12 months, with 57% of biologic-naive patients achieving minimal symptom expression.
Cartesian Therapeutics has achieved significant regulatory and clinical milestones in advancing its CAR-T therapy pipeline for autoimmune diseases, with the FDA accepting its investigational new drug application for a Phase 2 myositis (搜索) trial and continued progress in its pivotal myasthenia gravis (搜索) study.
The U.S. Food and Drug Administration (搜索) accepted Cartesian's IND application for its planned Phase 2 trial in myositis (搜索), marking the company's expansion into this autoimmune indication. The Phase 2 seamless adaptive clinical trial, designated TRITON, offers a potential opportunity for a single pivotal trial and is expected to commence in the first half of 2026.
Phase 2 Myositis Trial Design
The randomized, double-blind, placebo-controlled Phase 2 TRITON trial will assess Descartes-08 versus placebo in a 1:1 randomization administered as six once-weekly outpatient infusions without preconditioning chemotherapy. The study will enroll up to 50 participants with moderate to severe multi-refractory dermatomyositis (搜索) and antisynthetase syndrome (搜索).
The primary endpoint will assess safety and efficacy of Descartes-08 compared to placebo added to standard of care in participants with myositis (搜索) at Week 24. An interim analysis is planned after ten participants are enrolled and reach the primary endpoint, at which point sample size assumptions will be revised to support a potential seamless pivotal trial, pending FDA review based on preliminary efficacy data.
Phase 3 Myasthenia Gravis Progress
Enrollment remains on track in the Phase 3 AURORA trial of Descartes-08 in participants with myasthenia gravis (搜索). The trial was recently named to Nature Medicine's "Eleven clinical trials that will shape medicine in 2026" list. The randomized, double-blind, placebo-controlled study is designed to assess Descartes-08 versus placebo in 1:1 randomization administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor (搜索) autoantibody positive myasthenia gravis.
The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living score of three points or more at Month 4 compared to placebo.
Mechanism of Action and Efficacy Data
Two peer-reviewed journal articles published in Nature Medicine detailed the mechanism of action of Descartes-08 and reiterated data from the Phase 2b trial in myasthenia gravis (搜索) patients. The mechanism of action study observed that transient targeting of BCMA (搜索) with Descartes-08 achieved precision retuning of autoreactivity in myasthenia gravis. Descartes-08 eliminated pathogenic target BCMA+ cells with high levels of immune function while initiating a non-cellular immune reset and selectively modulating inflammatory proteins without depleting protective immune function.
The second publication outlined deep and durable responses observed through 12 months after a single course of therapy, consistent with previously announced 12-month data from the Phase 2b trial. The deepest and most compelling sustained responses were observed in patients without prior biologic therapies, with 57% of these seven participants achieving minimal symptom expression by Month 6 and maintaining it through Month 12.
Additional Clinical and Safety Findings
Beyond previously disclosed data, the company reported that after beginning medication tapering at Month 6 follow-up, the median reduction in prednisone daily dose was 55% at Month 12. Per trial protocol, changes in other MG-specific medications were not permitted.
Safety data remains consistent with no instances of cytokine release syndrome (搜索) or immune effector cell-associated neurotoxicity syndrome (搜索) reported, further supporting outpatient administration of Descartes-08. No immunosuppression is required to receive Descartes-08 treatment.
Pediatric Program Initiation
Cartesian announced the initiation of its Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including juvenile dermatomyositis (搜索). The FDA previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis, a rare pediatric autoimmune disorder.
Financial Outlook
The company expects current cash resources to support planned operations, including completion of its ongoing Phase 3 AURORA trial for Descartes-08 in myasthenia gravis (搜索) and initiation of its Phase 2 myositis (搜索) trial, through mid-2027.
"Following a year marked by significant progress advancing our autoimmune-focused pipeline, we are entering 2026 with strong momentum as we focus on advancing Descartes-08 across multiple indications," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Given the favorable safety profile observed in Descartes-08 supporting outpatient administration, we are confident that Descartes-08 could represent a meaningful addition to the MG treatment landscape."